Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
47.9M
-
Number of holders
-
292
-
Total 13F shares, excl. options
-
50M
-
Shares change
-
+161K
-
Total reported value, excl. options
-
$4.48B
-
Value change
-
+$16.7M
-
Put/Call ratio
-
0.12
-
Number of buys
-
131
-
Number of sells
-
-152
-
Price
-
$89.58
Significant Holders of HAEMONETICS CORP - Common Stock (HAE) as of Q3 2023
337 filings reported holding HAE - HAEMONETICS CORP - Common Stock as of Q3 2023.
HAEMONETICS CORP - Common Stock (HAE) has 292 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 50M shares
.
Largest 10 shareholders include Capital Research Global Investors (6.62M shares), BlackRock Inc. (5.78M shares), VANGUARD GROUP INC (5.38M shares), NEUBERGER BERMAN GROUP LLC (3.57M shares), WELLINGTON MANAGEMENT GROUP LLP (3.17M shares), STATE STREET CORP (1.74M shares), FRANKLIN RESOURCES INC (1.69M shares), FMR LLC (1.62M shares), GEODE CAPITAL MANAGEMENT, LLC (1.03M shares), and ROYCE & ASSOCIATES LP (948K shares).
This table shows the top 292 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.